Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/05/26
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?Investors Business Daily • 11/05/26
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business UpdatesBusiness Wire • 11/05/26
U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell LymphomaBusiness Wire • 11/04/26
Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 11/03/26
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Business Wire • 10/24/26
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal CancerBusiness Wire • 10/23/26
BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.Investors Business Daily • 10/22/26
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5Business Wire • 10/22/26
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026Business Wire • 10/19/26
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong BuyZacks Investment Research • 10/15/26
BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersZacks Investment Research • 09/01/26
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceBusiness Wire • 09/01/26
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer MedicinesBusiness Wire • 08/31/26
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal CancerBusiness Wire • 08/31/26
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 08/27/26